中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(8): 1790-1795

Establishment and validation of a noninvasive diagnostic model for chronic hepatitis B liver fibrosis based on LASSO regression

DOI: 10.3969/j.issn.1001-5256.2022.08.014

  • Department of Ultrasound, Changzhou Second People's Hospital, Nanjing Medical University, Changzhou, Jiangsu 213000, China

Research funding:

2019 General Medical Research Project of Jiangsu Provincial Health Commission (H201952)

More Information
  • Corresponding author: ZHU Weiwen, ww1234xiao@126.com(ORCID: 0000-0003-0159-2784)
  • Received Date: 2022-01-07
  • Accepted Date: 2022-03-16
  • Published Date: 2022-08-20
    Abstract
  •   Objective  To establish a noninvasive diagnostic model for chronic hepatitis B (CHB) liver fibrosis based on LASSO regression using serological parameters, and to investigate the value of this model in the diagnosis of CHB liver fibrosis.  Methods  A total of 240 patients who were diagnosed with CHB in Changzhou Second People's Hospital, Nanjing Medical University, from September 2019 to September 2021 were enrolled as subjects, and according to the results of liver biopsy and pathology, they were divided into significant liver fibrosis (stage F2-F4) group with 175 patients and non-significant liver fibrosis (stage F0-F1) group with 65 patients. The two groups were compared in terms of sex, age, blood biochemical parameters, and liver stiffness measurement (LSM) measured by two-dimensional shear wave elastography, and LASSO regression and the multivariate logistic regression analysis were used screen out the risk factors for liver fibrosis. A nomogram model was established and then verified by the receiver operating characteristic (ROC) curve, calibration curve, and decision curve. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups.  Results  There were significant differences between the patients with stage F3/F4 liver fibrosis and those with stage F2/F0-F1 liver fibrosis in age, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, total bilirubin, platelet count, procollagen type Ⅲ, type Ⅳ collagen, hyaluronic acid, and LSM (all P < 0.05). Five important variables were screened out by LASSO regression, and the logistic regression analysis showed that hyaluronic acid (odds ratio [OR]=1.432, P < 0.05), type Ⅳ collagen (OR=1.243, P < 0.05), procollagen type Ⅲ(OR=1.146, P < 0.05), and LSM (OR=1.656, P < 0.05) were the independent risk factors for liver fibrosis, while platelet count (OR=0.567, P < 0.05) was a protective factor. Compared with the patients with stage F2/F0-F1 liver fibrosis, the patients with stage F3/F4 liver fibrosis had significantly higher score of the nomogram model, LSM, aspartate aminotransferase-to-platelet ratio index (APRI), King score, Forns index, and fibrosis-4 (FIB-4) index (all P < 0.05). The ROC curve was used to analyze the predictive value of the nomogram model, and the results showed an area under the ROC curve of 0.876, which was significantly higher than that of LSM, APRI, King score, Forns index, and FIB-4 (all P < 0.05). Calibration curve and decision curve showed that the nomogram model had acceptable consistency and benefit.  Conclusion  The noninvasive nomogram model based on LASSO regression is established by using serum parameters including hyaluronic acid, type Ⅳ collagen, procollagen type Ⅲ, platelet count, and LSM, and as a quantitative tool for the clinical diagnosis of CHB liver fibrosis, it has a high diagnostic efficiency and thus holds promise for clinical application.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    ALTAMIRANO-BARRERA A, BARRANCO-FRAGOSO B, MÉNDEZ-SÁNCHEZ N. Management strategies for liver fibrosis[J]. Ann Hepatol, 2017, 16(1): 48-56. DOI: 10.5604/16652681.1226814.
    [2]
    KHAN S, SAXENA R. Regression of hepatic fibrosis and evolution of cirrhosis: a concise review[J]. Adv Anat Pathol, 2021, 28(6): 408-414. DOI: 10.1097/PAP.0000000000000312.
    [3]
    LEMMER A, VANWAGNER LB, GANGER D. Assessment of advanced liver fibrosis and the risk for hepatic decompensation in patients with congestive hepatopathy[J]. Hepatology, 2018, 68(4): 1633-1641. DOI: 10.1002/hep.30048.
    [4]
    AGBIM U, ASRANI SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 361-374. DOI: 10.1080/17474124.2019.1579641.
    [5]
    LOOMBA R, ADAMS LA. Advances in non-invasive assessment of hepatic fibrosis[J]. Gut, 2020, 69(7): 1343-1352. DOI: 10.1136/gutjnl-2018-317593.
    [6]
    CHENG CH, CHU CY, CHEN HL, et al. Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C[J]. J Microbiol Immunol Infect, 2020, 53(4): 542-549. DOI: 10.1016/j.jmii.2019.09.002.
    [7]
    CUI AL, WANG JB, XU LL, et al. Evaluation of two-dimensional shear wave elastography and transient elastography in the diagnosis of hepatic fibrosis in patients with chronic hepatitis B[J]. Clin Ultras Med, 2018, 20(12): 819-822. DOI: 10.3969/j.issn.1008-6978.2018.12.008.

    崔艾琳, 王佳冰, 徐莉力, 等. 二维剪切波弹性成像与瞬时弹性成像对慢性乙型肝炎患者肝纤维化诊断效能的探讨[J]. 临床超声医学杂志, 2018, 20(12): 819-822. DOI: 10.3969/j.issn.1008-6978.2018.12.008.
    [8]
    JIANG W, HUANG S, TENG H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis[J]. BMJ Open, 2018, 8(8): e021787. DOI: 10.1136/bmjopen-2018-021787.
    [9]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on diagnosis and treatment of liver fibrosis (2019)[J] J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
    [10]
    ABDEL-HAMEED EA, ROUSTER SD, KOTTILIL S, et al. The enhanced liver fibrosis index predicts hepatic fibrosis superior to FIB4 and APRI in HⅣ/HCV infected patients[J]. Clin Infect Dis, 2021, 73(3): 450-459. DOI: 10.1093/cid/ciaa646.
    [11]
    MEDHIOUB M, BEN SALAH W, KHSIBA A, et al. Performance of FIB4 and APRI scores for the prediction of fibrosis in patients with chronic hepatitis B virus infection[J]. Tunis Med, 2020, 98(12): 998-1004.
    [12]
    CHANG ML, YANG SS. Metabolic signature of hepatic fibrosis: from individual pathways to systems biology[J]. Cells, 2019, 8(11). DOI: 10.3390/cells8111423.
    [13]
    IQBAL U, DENNIS BB, LI AA, et al. Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis[J]. Hepatol Int, 2019, 13(1): 84-90. DOI: 10.1007/s12072-018-9918-2.
    [14]
    CABALLERÍA L, TORÁN P, CABALLERÍA J. Markers of hepatic fibrosis[J]. Med Clin (Barc), 2018, 150(8): 310-316. DOI: 10.1016/j.medcli.2017.08.009.
    [15]
    UEDA J, YOSHIDA H, MAMADA Y, et al. Evaluation of the impact of preoperative values of hyaluronic acid and type iv collagen on the outcome of patients with hepatocellular carcinoma after hepatectomy[J]. J Nippon Med Sch, 2018, 85(4): 221-227. DOI: 10.1272/jnms.JNMS.2018_85-34.
    [16]
    SULYOK M, FERENCI T, MAKARA M, et al. Hepatic fibrosis and factors associated with liver stiffness in HⅣ mono-infected individuals[J]. Peer J, 2017, 5: e2867. DOI: 10.7717/peerj.2867.
    [17]
    ZHANG R, CHEN J, JIANG Y, et al. Prognostic nomogram for hepatocellular carcinoma with fibrosis of varying degrees: a retrospective cohort study[J]. Ann Transl Med, 2020, 8(21): 1429. DOI: 10.21037/atm-20-3267.
    [18]
    XU DX, ZHANG F. Expression levels of coagulation indicators in patients with different stages of hepatitis B virus infection[J]. Chin J Med Offic, 2020, 48(11): 1349-1350, 1353. DOI: 10.16680/j.1671-3826.2020.11.32.

    许德翔, 张飞. 不同阶段乙型肝炎病毒感染患者凝血功能指标表达水平分析[J]. 临床军医杂志, 2020, 48(11): 1349-1350, 1353. DOI: 10.16680/j.1671-3826.2020.11.32.
    [19]
    CAMPOS-MURGUÍA A, RUIZ-MARGÁIN A, GONZÁLEZ-REGUEIRO JA, et al. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2020, 26(39): 5919-5943. DOI: 10.3748/wjg.v26.i39.5919.
    [20]
    BERARDI G, MORISE Z, SPOSITO C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis[J]. J Hepatol, 2020, 72(1): 75-84. DOI: 10.1016/j.jhep.2019.08.032.
    [21]
    XIONG J, LIN DN, WENG WZ, et al. Assessment of hepatitis B virus associated liver fibrosis by FIB-4 combined with serum PCⅢ, ⅣC[J]. Int J Virol, 2020, 27(5): 403-406. DOI: 10.3760/cma.j.issn.1673-4092.2020.05.012.

    熊静, 林登娜, 翁伟镇, 等. FIB-4联合血清PCⅢ、ⅣC评估乙型肝炎病毒相关肝纤维化[J]. 国际病毒学杂志, 2020, 27(5): 403-406. DOI: 10.3760/cma.j.issn.1673-4092.2020.05.012.
    [22]
    XU W, CHENG Y, TU B. Construction and validation of a nomogram for predicting the risk of portal vein thrombosis after splenectomy in patients with hepatitis B cirrhosis[J]. J South Med Univ, 2020, 40(9): 1265-1272. DOI: 10.12122/j.issn.1673-4254.2020.09.07.

    徐伟, 程瑶, 涂兵. 乙型肝炎肝硬化患者行脾切除术后门静脉血栓形成的列线图预测模型的建立与验证[J]. 南方医科大学学报, 2020, 40(9): 1265-1272. DOI: 10.12122/j.issn.1673-4254.2020.09.07.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (763) PDF downloads(72) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return